Effect of Ertugliflozin on Cardiac Function in Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 102 participants.

Also called NCT03717194

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 102 participants (enrolled count) (from the registry)
Sponsor
Soo Lim (from the registry)
Registry
  • NCT NCT03717194
Other papers using this trial's data
  • Effect of ertugliflozin on left ventricular function in type 2 diabetes and pre-heart failure: the Ertu-GLS randomized clinical trial Cardiovascular diabetology, 2024-10-22 DOI, PubMed 39438942, PMC11515769 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03717194. Randomized; quadruple masking; primary purpose treatment. Start 2019-06-01 (actual); primary completion 2022-12-31 (actual). Results posted on 2024-11-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Ertugliflozin on Cardiac Function in Diabetes
Acronym
ERTU-GLS
Condition
Type2 Diabetes
Condition
Heart Failure
Intervention (Drug)
Ertugliflozin
Intervention (Drug)
Placebo
Lead sponsor
Soo Lim (class: other)
Collaborator
MSD Korea Ltd. (class: industry)

Record details

Record id
cardio:ct-nct03717194
Content hash
f96cce059d59d85ec1b6e5d625c524885a7fb7ede1dc3fdacf5a8f2f64d1fd29